Caverject User Study

NCT01008605

Last updated date
Study Location
Pfizer Investigational Site
Overland Park, Kansas, 66211, United States
Contact
1-800-718-1021

FOR MORE INFORMATION

Contact a representative by phone, email, or visiting the study website. Please see the references below:

By phone

Pfizer Clinical Trials Contact Center

1-800-718-1021

By email

Contact

[email protected]

Call Now

Eligibility Criteria
condition
The disease, disorder, syndrome, illness, or injury that is being studied.
Erectile Dysfunction
Sex
Male
Age
Pediatric Trials: 0-17 Years
Adult Trials: 18+ Years
40-70 years
Inclusion Criteria
The factors, or reasons, that allow a person to participate in a clinical study.
Show details

Age 40 to 70

Exclusion Criteria
The factors, or reasons, that prevent a person from participating in a clinical study.
Show details


Prior syringe skills

NEED INFO?

Questions about a trial? Call or email to reach a Pfizer Clinical Trial Contact Center Representative

Pfizer Clinical Trials Contact Center

1-800-718-1021

[email protected]

TRY A NEW SEARCH

Search for Clinical Trials by condition, keyword or trial number. Share your location or enter your city or zip code to find studies near you.

Based on your search, you may also be interested in

Erectile DysfunctionA Relative Bioavailability Study Between Two Formulations Of Sildenafil Citrate NCT00904748
  1. Braganca Paulista, SP
Male
18 Years+
years
MULTIPLE SITES
Erectile DysfunctionA Study to Evaluate Self-esteem and Relationships in Males With Erectile Dysfuntion NCT00648596
  1. Oulu,
  2. Tampere,
  3. Turku,
  4. Clermont Ferrand,
  5. Le Kremlin Bicentre,
  6. Lyon Cedex 03,
  7. MARSEILLE Cedex 20,
  8. Neuilly-sur-seine,
  9. NICE Cedex 01,
  10. Nimes,
  11. Toulouse,
  12. Bari,
  13. Catania,
  14. Gallarate (va),
  15. Modena,
  16. Padova,
  17. Roma,
  18. Siena,
  19. Torino,
  20. Krakow,
  21. Lodz,
  22. Lublin,
  23. Olsztyn,
  24. Szczecin,
  25. Warszawa,
  26. Moscow, Russia
  27. Moscow, Russia
  28. Moscow, Russia
  29. Moscow, Russia
  30. Moscow, Russia
  31. Novosibirsk, Russia
  32. Rostov-on-don, Russia
  33. St. Petersburg, Russia
  34. St. Petersburg, Russia
  35. Barnaul,
  36. Ekaterinburg,
  37. Moscow,
  38. Moscow,
  39. Moscow,
  40. Nizhny Novgorod,
  41. Novosibirsk,
  42. Saint-Petersburg,
  43. Saint-Petersburg,
  44. San Juan, Alicante
  45. Barakaldo, Vizcaya
  46. Barcelona,
  47. Madrid,
  48. Madrid,
  49. Madrid,
  50. Valencia,
  51. Valencia,
  52. Zaragoza,
  53. Karlshamn,
  54. Malmo,
  55. Skovde,
  56. Stockholm,
  57. Varnamo,
  58. Vastervik,
  59. Bodelwyddan, Denbighshire
  60. South Yorkshire, Dn1 2et
  61. Belmont, Durham
  62. Blackpool, Lancashire
  63. Urmston, Manchester
  64. Ashford, Middlesex
  65. Nr Lichfield, Staffordshire
  66. Addlestone, Surrey
  67. Taunton, Ta1 5da
Male
18 Years+
years
MULTIPLE SITES
Advanced Information
Descriptive Information
Brief Title  ICMJE Caverject User Study
Official Title  ICMJE Representative Users Study Of Operating Characteristics Of The Caverject Delivery System.
Brief Summary The purpose of this study is to demonstrate the usability of the system.
Detailed Description demonstrate usability
Study Type  ICMJE Interventional
Study Phase  ICMJE Phase 3
Study Design  ICMJE Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Condition  ICMJE Erectile Dysfunction
Intervention  ICMJE Other: delivery system
syringe
Study Arms  ICMJE Experimental: Caverject Impulse
representative users
Intervention: Other: delivery system
Publications * Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruitment Information
Recruitment Status  ICMJE Completed
Actual Enrollment  ICMJE
 (submitted: March 7, 2011)
48
Original Estimated Enrollment  ICMJE
 (submitted: November 5, 2009)
50
Actual Study Completion Date  ICMJE February 2011
Actual Primary Completion Date February 2011   (Final data collection date for primary outcome measure)
Eligibility Criteria  ICMJE

Inclusion Criteria:

Age 40 to 70

Exclusion Criteria:

Prior syringe skills

Sex/Gender  ICMJE
Sexes Eligible for Study:Male
Ages  ICMJE 40 Years to 70 Years   (Adult, Older Adult)
Accepts Healthy Volunteers  ICMJE Yes
Contacts  ICMJE Contact information is only displayed when the study is recruiting subjects
Listed Location Countries  ICMJE United States
Removed Location Countries  
 
Administrative Information
NCT Number  ICMJE NCT01008605
Other Study ID Numbers  ICMJE A6711035
Has Data Monitoring Committee No
U.S. FDA-regulated Product Not Provided
IPD Sharing Statement  ICMJE Not Provided
Responsible Party Pfizer
Study Sponsor  ICMJE Pfizer
Collaborators  ICMJE Not Provided
Investigators  ICMJE
Study Director:Pfizer CT.gov Call CenterPfizer
PRS Account Pfizer
Verification Date April 2012

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP